My Association Login

Merit Medical Systems Announces Three-Part Deal With Vysera Biomedical Limited

Tuesday, 27 October 2009

SOUTH JORDAN, Utah, Oct. 27, 2009 (GLOBE NEWSWIRE) -- Merit Medical Systems,
Inc. (Nasdaq:MMSI), a leading manufacturer and marketer of proprietary
disposable devices used primarily in cardiology, radiology and gastroenterology
procedures, announced today that the Company has completed a three-part deal
with Vysera Biomedical Limited located in Galway, Ireland, which will give Merit
access to certain intellectual property and know-how for valve technology,
opportunities to commercialize certain biomaterial technology and equity
ownership in Vysera.

The transactions provide Merit with an exclusive license for certain valve
technology that may be incorporated into non-vascular stents, specifically
esophageal stents, to address acid reflux conditions. Secondly, the
transactions provide Merit with an exclusive license for the development and use
of certain biomaterial technology for the coating of selected non-vascular
stents and gastrointestinal and drainage catheters.

Finally, the transactions provide Merit with an equity investment of
approximately $2.4 million, which will give Merit an approximate 14.45%
fully-diluted participating equity interest in Vysera. Additionally, Fred P.
Lampropoulos, Merit's Chairman and Chief Executive Officer, has been elected as
a director of Vysera.

The total amount paid by Merit to Vysera in license fees and equity purchase
payments is approximately $3.9 million.

"We are pleased to join the Enterprise Equity Investment Fund Limited,
Enterprise Ireland, the Western Development Commission and other Vysera
investors in what we believe are cutting-edge device and biomaterial
opportunities," Lampropoulos said. "We believe the licensed technologies will be
beneficial for products developed for Merit's Endotek division as well as our
interventional radiology product group."

Donal Devery, Chief Executive Officer of Vysera, said, "We look forward to the
association with Mr. Lampropoulos and Merit Medical Systems. Their long record
of innovation and growth in addition to their marketing resources with global
reach will expedite the commercialization of our technology in the medical
device market."

Further details of this transaction will be discussed during Merit's investor
conference call to be held today at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00
p.m. Mountain, and 2:00 p.m. Pacific). The telephone numbers to call are
(domestic) 877-941-1465; and (international) 480-629-9678. A live webcast will
also be available for the conference call at www.merit.com and
www.fulldisclosure.com.

ABOUT MERIT

Founded in 1987, Merit Medical Systems, Inc. is engaged in the development,
manufacture and distribution of proprietary disposable medical devices used in
interventional and diagnostic procedures, particularly in cardiology, radiology
and gastroenterology. Merit serves client hospitals worldwide with a domestic
and international sales force totaling approximately 125 individuals. Merit
employs approximately 1,880 people worldwide, with facilities in Salt Lake City
and South Jordan, Utah; Angleton, Texas; Richmond, Virginia; Maastricht and
Venlo, The Netherlands; and Galway, Ireland.

The Merit Medical Systems, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=3282

Statements contained in this release which are not purely historical, are
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995 and are subject to risks and uncertainties such as
those described in Merit's Annual Report on Form 10-K for the year ended
December 31, 2008. Such risks and uncertainties include risks relating to:
infringement of Merit's technology or the assertion that Merit's technology
infringes the rights of other parties; downturn of the national economy and its
affect on Merit's revenues, collections and supplier relations; termination of
supplier relationships, or failure of suppliers to perform; product recalls and
product liability claims; delays in obtaining regulatory approvals, or the
failure to maintain such approvals; inability to successfully manage growth
through acquisitions, including the inability to commercialize the Vysera
technology as currently anticipated; concentration of Merit's revenues among a
few products and procedures; development of new products and technology that
could render Merit's products obsolete; market acceptance of new products;
introduction of products in a timely fashion; price and product competition;
availability of labor and materials; cost increases; fluctuations in and
obsolescence of inventory; volatility of the market price of Merit's common
stock; foreign currency fluctuations; changes in key personnel; work stoppage or
transportation risks; modification or limitation of governmental or private
insurance reimbursement; changes in health care markets related to health care
reform initiatives; impact of force majeure events on Merit's business,
including severe weather conditions; failure to comply with applicable
environmental laws and other factors referred to in Merit's Annual Report on
Form 10-K for the year ended December 31, 2008, and other reports filed with the
Securities and Exchange Commission. All subsequent forward-looking statements
attributable to Merit or persons acting on its behalf are expressly qualified in
their entirety by these cautionary statements. Actual results will differ, and
may differ materially, from anticipated results. Financial estimates are subject
to change and are not intended to be relied upon as predictions of future
operating results, and Merit assumes no obligation to update or disclose
revisions to those estimates.
logo - Twitter